---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-017792"
form_type: "8-K"
ticker: "FNCHQ"
cik: "0001733257"
company_name: "Finch Therapeutics Group, Inc."
filed_at: "2022-08-25T23:59:59+00:00"
generated_at: "2026-06-23T21:25:10.673476+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Takeda terminates collaboration; Finch regains full rights to IBD candidates FIN-524 and FIN-525

## Summary
- Takeda terminated collaboration for convenience effective Nov 17, 2022; Finch regains worldwide rights to FIN-524 and FIN-525.
- Finch received over $44M total from Takeda ($10M upfront, $4M milestones, over $30M R&D reimbursement).
- Finch will receive royalty-free license to all data and intellectual property generated during the collaboration.
- Finch is conducting a portfolio review and assessing financial and strategic impact of the termination.
- No new revenue or guidance provided; future development path for IBD candidates uncertain.

## SEC filing metadata
- accession: 0000950170-22-017792
- form_type: 8-K
- ticker: FNCHQ
- cik: 0001733257
- company_name: Finch Therapeutics Group, Inc.
- filed_at: 2022-08-25T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1733257/000095017022017792/0000950170-22-017792-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1733257/000095017022017792/fnch-20220819.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-017792
- JSON: https://secwatch.observer/filing/0000950170-22-017792.json
- Plain text: https://secwatch.observer/filing/0000950170-22-017792.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.